Tenaya Therapeutics

Tenaya Therapeutics

Yahoo Finance • 3 days ago

Tenaya Therapeutics Appoints Eric Hyllengren As CFO

(RTTNews) - Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, said on Monday that it has appointed Eric Hyllengren as Chief Financial Officer with effect from July 13. Hyllengren most recently served as CFO of Zura... Full story

Yahoo Finance • 3 days ago

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address t... Full story

Yahoo Finance • 29 days ago

Tenaya's TN-201 Gene Therapy Shows Sustained Cardiac Improvements In MYBPC3-Associated HCM

(RTTNews) - Tenaya Therapeutics, Inc. (TNYA) announced new interim data from its ongoing MyPEAK-1 Phase 1b/2 trial evaluating TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM). The results were... Full story

Yahoo Finance • 2 months ago

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of TN-401 Activity in... Full story

Yahoo Finance • 2 months ago

US High Growth Tech Stocks To Watch Now

In the last week, the market has stayed flat, yet it is up 30% over the past year with earnings forecast to grow by 16% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate stro... Full story

Yahoo Finance • 2 months ago

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT Additional Presentations at ASGCT Showcase Tenaya’s Work with Patients to Advance Gene Therapy and Early-... Full story

Yahoo Finance • 4 months ago

Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Alnylam Pharmaceuticals (NasdaqGS:ALNY) has signed a multi year research collaboration with Tenaya... Full story

Yahoo Finance • 4 months ago

Tenaya Enters Research Collaboration With Alnylam; To Receive Up To $10 Mln In Upfront Payments

(RTTNews) - Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY), to discover human genetic targets for the potential development of disease-modifying treatments for cardiovascular dis... Full story

Yahoo Finance • 7 months ago

Tenaya Therapeutics Prices 50 Mln Unit Offering At $60 Mln, Clinical Hold Lifted On TN-201

(RTTNews) - Tenaya Therapeutics, Inc. (TNYA) Friday announced that it has priced a $60 million public offering of 50 million units at $1.20 per unit. Each unit consists of one share of common stock and a warrant to purchase one share at $1... Full story

Yahoo Finance • 7 months ago

Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address t... Full story

Yahoo Finance • 7 months ago

Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address t... Full story

Yahoo Finance • 8 months ago

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses Longer-term Follow Up of Cohort 1 Patien... Full story

Yahoo Finance • 8 months ago

Tenaya Therapeutics falls after FDA clinical hold on heart disorder trial

[Heart, stethoscope and EKG] MarsBars/E+ via Getty Images Tenaya Therapeutics (TNYA [https://seekingalpha.com/symbol/TNYA]) stock fell after its mid-stage trial for TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy,... Full story

Yahoo Finance • 8 months ago

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking Presentation on Sunday to Showc... Full story

Yahoo Finance • 9 months ago

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address t... Full story

Yahoo Finance • 9 months ago

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address t... Full story

Yahoo Finance • 9 months ago

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address t... Full story

Yahoo Finance • 10 months ago

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address... Full story

Yahoo Finance • 10 months ago

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No Approved Therapeutics Gen... Full story

Yahoo Finance • 10 months ago

Tenaya therapeutics CMO Tingley sells $6.3k in shares

Chief Medical Officer of Tenaya Therapeutics (NASDAQ:TNYA), Whittemore Tingley, sold a total of 5,053 shares of common stock on August 18, 2025. The sales were executed in three separate transactions, with the price per share at $1.253.... Full story